Convalescent Plasma To Limit COVID-19 Associated Complications

Status Not yet recruiting

Clinical Trial Summary

This is a randomized, blinded phase 2 trial to assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with a symptom onset between 3 and 7 days OR within 72 hours of hospitalization.

Clinical Trial Description

Yale University is conducting this trial as a single site in collaboration with the New York University protocol. That trial is registered separately in ClinicalTrials.gov (NCT04364737), with Einstein College of medicine listed as a collaborator. Yale has applied for its own IND, which is pending at the time of this registration. Yale will be using the same data capture system and central COVID specific-data safety monitoring board (DSMB) as the other sites. ;

Study Design

Related Conditions & MeSH terms

Corona Virus Infection
Coronavirus Infections
Severe Acute Respiratory Syndrome

Clinical Trial Details

NCT number	NCT04404634
Study type	Interventional
Source	Yale University
Contact	Mahalia Desruisseaux, MD
Phone	203-737-4057
Email	mahalia.desruisseaux@yale.edu
Status	Not yet recruiting
Phase	Phase 2
Start date	May 2020
Completion date	January 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04384445` - Zofin (Organicell Flow) for Patients With COVID-19	Phase 1/Phase 2
Completed	`NCT04578210` - Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia	Phase 1/Phase 2
Completed	`NCT05065827` - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Completed	`NCT04720794` - A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion	N/A
Enrolling by invitation	`NCT04659486` - Adolescents With COVID-19/MIS-C at HCFMUSP	N/A
Completed	`NCT04598620` - Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
Completed	`NCT05517941` - Effect of Active Cycle Breathing Technique Along With Incentive Spirometer on COVID19 Patient	N/A
Recruiting	`NCT04565782` - Corona Virus Infection Among Liver Transplant Recipients
Recruiting	`NCT04480333` - Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831	Phase 1
Active, not recruiting	`NCT04558476` - Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation	Phase 2
Completed	`NCT04526769` - Detecting SARS-CoV-2 in Tears
Completed	`NCT05639998` - BBV152/BBV154 Heterologus Prime-Boost Study	Phase 2
Completed	`NCT04523246` - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents	Early Phase 1
Completed	`NCT05736926` - Anal Fissure Among Survivors of COVID-19 Virus Infection.
Withdrawn	`NCT04386447` - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19	Phase 2
Recruiting	`NCT04583566` - Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients
Completed	`NCT04643678` - Anakinra in the Management of COVID-19 Infection	Phase 2/Phase 3
Recruiting	`NCT04579588` - Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Terminated	`NCT03331445` - Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections	Phase 2
Recruiting	`NCT04573348` - T Cells Response to SARS COV 2 Peptides